Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?The Motley Fool • 11/11/23
Merck's drug Keytruda recommended for EU approval for biliary tract cancerProactive Investors • 11/10/23
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract CancerBusiness Wire • 11/10/23
Merck Foundation CEO and African First Ladies discussed Healthcare Capacity Building and Breaking Infertility Stigma at Africa Asia Luminary 2023Business Wire • 11/06/23
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract CancerBusiness Wire • 11/01/23
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following NephrectomyBusiness Wire • 11/01/23
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?The Motley Fool • 10/31/23
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug ConjugateBusiness Wire • 10/30/23
Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV ShotInvestopedia • 10/26/23